1. Inici
  2. Projectes i Estudis Clínics
  3. Exploring the relationship between pharmacokinetics and clinical outcomes in hemophilia A patients who have switched treatment from a previous FVIII product to Jivi in real-world practice.

Exploring the relationship between pharmacokinetics and clinical outcomes in hemophilia A patients who have switched treatment from a previous FVIII product to Jivi in real-world practice.

Dades bàsiques

Protocol:
WAPPs-Hemo
EURDRACT:
NCT:
Centre:
HOSPITAL UNIVERSITARI I POLITÈCNIC LA FE
Any inici:
Any de finalització:
ESTUDIO OBSERVACIONAL

Documents

  • No hi ha documents

Participants

Grups d'Investigació

Finançadors - Promotors

HEMALYTIC INC.

Resultats de l'Assaig Clínic

[Translated article] New challenges in advanced therapies.

Megías-Vericat JE; (...); Poveda Andrés JL

Article. 10.1016/j.farma.2024.05.001. 2024

  • Open Access.

[Translated article] Pharmacokinetic-guided switching from standard half-life factor VIII to extended half-life pegylated factor VIII in haemophilia A therapy in clinical practice.

Chovi-Trull, Maria; (...); Andres, Jose Luis Poveda

Article. 10.1016/j.farma.2024.12.007. 2025


A post hoc comparative real-world analysis of HEAD-US score for joint health assessment of patients with severe haemophilia A and B in Spain

Alvarez-Roman, Maria Teresa; (...); Kim, Hae Kyung

Article. 10.1111/hae.14924. 2024


Benefits of physical activity self-monitoring in patients with haemophilia: a prospective study with one-year follow-up.

Pérez-Alenda S; (...); Núñez-Cortés R

Article. 10.1111/hae.14988. 2024

  • Open Access.

Bladder cancer patients have increased NETosis and impaired DNaseI-mediated NET degradation that can be therapeutically restored in vitro.

Herranz R; (...); Medina P

Article. 10.3389/fimmu.2023.1171065. 2023

  • Open Access.

Comparative analysis of Hemophilia Early Arthropathy Detection with Ultrasound (HEAD-US) scores in persons with nonsevere hemophilia A and B reveals a high degree of joint damage in both disease types

Jimenez-Yuste, Victor; (...); Kim, Hae Kyung

Letter. 10.1016/j.rpth.2023.102207. 2023

  • Open Access.

Comprehensive Screening of Genetic Variants in the Coding Region of F8 in Severe Hemophilia A Reveals a Relationship with Disease Severity in a Colombian Cohort.

Sarmiento Doncel, Samuel; (...); Lopez Guerrero, Jose A

Article. 10.3390/life14081041. 2024

  • Open Access.

Cost-effectiveness and cost-utility analysis of haemate-P versus other von willebrand disease treatments in Spain.

Megias-Vericat, Juan E; (...); Yan, Songkai

Article. 10.1080/13696998.2025.2474886. 2025


Delving into the clinical impact of NETs in pediatric cancer.

Benavent N; (...); Medina P

Article. 10.1038/s41390-024-03437-4. 2024


Determinants of bleeding before and during immune tolerance in 222 boys with severe hemophilia A and inhibitors >5 BU.

Fischer K; (...); Königs C

Article. 10.1182/bloodadvances.2023011442. 2024

  • Open Access.

Development and testing of a mobile app for systematic collection of patient-reported outcomes (PROs) in patients with hemophilia.

Megias-Vericat, J E; (...); Poveda Andres, J L

Letter. 10.1016/j.thromres.2024.109122. 2024


Haemophilic arthropathy: basic protocols for clinical examination and imaging.

Querol, F.; (...); Perez-Alenda, S.

Article. 10.1097/MBC.0000000000001215. 2023


Haemotrack: Musculoskeletal management in haemophilia with physiotherapist-driven digital solutions

Perez-Alenda, Sofia; (...); Aguilar-Rodriguez, Marta

Meeting Abstract. 2024


Humanistic burden of haemophilia A without inhibitors: A cross-sectional analysis of the HemoLIFE study.

Alvarez-Roman, Maria Teresa; (...); Soto-Ortega, Inmaculada

Article. 10.1111/hae.15057. 2024

  • Open Access.

Management of Urgent Bleeding in Patients with Hemophilia A: Focus on the Use of Emicizumab.

Jiménez-Yuste V; (...); Rodríguez-López M

Article. 10.1055/s-0044-1785525. 2024

  • Open Access.

Mental, emotional and social dimensions of quality of life and their relationship with physical and functional status in adults with haemophilia.

Rodríguez MA; (...); Chimeno-Hernández A

Article. 10.1016/j.thromres.2024.109181. 2024

  • Open Access.

Moderate haemophilia A: Recommendations from a Spanish panel of experts.

Álvarez Román MT; (...); López-Jaime FJ

Article. 10.1111/hae.15110. 2024

  • Open Access.

New challenges of advanced therapies.

Megías-Vericat JE; (...); Poveda Andrés JL

Article. 10.1016/j.farma.2023.11.008. 2024

  • Open Access.

Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Treated with Pegcetacoplan: Real Life Experience

Vallejo, Carlos; (...); Vara, Miriam

Meeting Abstract. 10.1182/blood-2023-185570. 2023


Pharmacogenetics in Response to Biological Agents in Inflammatory Bowel Disease: A Systematic Review.

Ballesta-Lopez, Octavio; (...); Poveda-Andres, Jose Luis

Article. 10.3390/ijms26041760. 2025

  • Open Access.

Real-world analysis of the PK-guided switch from standard half-life factor VIII to efmoroctocog alfa.

Megias-Vericata, J. E.; (...); Poveda Andres, J L

Letter. 10.1016/j.thromres.2023.11.023. 2023


Real-world data in patients with congenital hemophilia and inhibitors: final data from the FEIBA Global Outcome (FEIBA GO) study.

Ettingshausen CE; (...); Windyga J

Article. 10.1177/20406207231184323. 2023

  • Open Access.

Suitability and readiness assessment of organizational resources for the implementation of gene therapy in hemophilia in Spain and Portugal: A survey-based study.

Villas JMC; (...); Álvarez-Román MT

Letter. 10.1016/j.thromres.2024.109180. 2024


Thrombotic risk and features of patients with inferior vena cava agenesis: a multicentre, retrospective, observational study.

Bravo-Perez, Carlos; (...); Corral, Javier

Article. 10.1016/S2352-3026(24)00138-8. 2024


Campos d'Estudi

Compartir el projecte